Targeted Drug Improves Survival in Advanced Endometrial Cancer
Quick Summary Merck’s sac-TMT (anti-TROP2 antibody-drug conjugate) improved overall survival and progression-free survival in advanced or recurrent endometrial cancer after prior platinum chemotherapy and immunotherapy, according to Phase 3 TroFuse-005 trial (N=776). The drug also improved response rate compared to standard chemotherapy. Safety profile consistent with earlier studies. Exact survival
May 29, 2026
No Comments
